Literature DB >> 14612942

Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.

Orazio Schillaci1, Angela Spanu, Francesco Scopinaro, Antonio Falchi, Vito Corleto, Roberta Danieli, Pietro Marongiu, Nicola Pisu, Giordano Madeddu, Gianfranco Delle Fave, Giuseppe Madeddu.   

Abstract

To investigate somatostatin receptor scintigraphy (SRS) usefulness compared to conventional imaging procedures (CIP) in non-functioning gastroenteropatic (GEP) neuroendocrine tumors, we studied 40 patients, 30 in follow-up (FU) after previous operation for primary tumor (27 cases) or non-operable for disseminated metastases (3 cases), and 10 in the phase of initial diagnosis and staging (IDS). All patients were asymptomatic for hormone overexpression, with slightly high serum chromogranine A in 6 FU. The definitive diagnosis was obtained by surgery, laparotomy or percutaneous CT/US guided biopsy. Within 1 month before scintigraphy, all patients had undergone at least 2 of 3 CIP (CT, MRI and US); 4 and 24 h after 250 MBq 111In-pentetreotide i.v. injection, whole body scanning, planar and SPECT over the abdomen or other suspect regions were performed. Globally, 135 neoplastic lesions (84 hepatic, 34 abdominal extra-hepatic and 17 extra-abdominal) were ascertained in 32/40 patients; SPECT was positive in 29 cases, CIP in 28 and planar in 20, while all 3 procedures were true negative in the remaining 8 cases. Per patient sensitivity and accuracy were significantly higher at SPECT and CIP than planar. SPECT showed a significantly higher per lesion sensitivity (89.6%) than CIP (72.6%) and planar (53.3%) while CIP sensitivity was significantly higher than planar. SPECT correctly modified CIP patient classification and thus management in 18.7% of patients, while it downstaged the disease in 9.4% in respect of CIP; planar was incorrect in 51.3% of cases. SPECT and CIP combined use achieved 100% accuracy and correctly classified all patients. 111In-pentetreotide SRS, particularly SPECT, is a useful diagnostic tool in the detection of non-functioning GEP tumors, contributing to correct patient classification and appropriate therapeutic strategy. SPECT proved more sensitive than CIP, but their combined use achieved the highest accuracy values and gave the most accurate disease staging.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612942

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  Pancreatic neuroendocrine tumors: overview of recent advances and diagnosis.

Authors:  Robert T Jensen
Journal:  J Gastrointest Surg       Date:  2006-03       Impact factor: 3.452

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Non-functioning gastroenteropancreatic (GEP) tumors: a 111In-Pentetreotide SPECT/CT diagnostic study.

Authors:  Angela Spanu; Orazio Schillaci; Bastiana Piras; Diego F Calvisi; Antonio Falchi; Roberta Danieli; Susanna Nuvoli; Franca Dore; Giuseppe Madeddu
Journal:  Am J Nucl Med Mol Imaging       Date:  2017-09-01

Review 4.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

5.  X-linked hyper-IgM syndrome associated with poorly differentiated neuroendocrine tumor presenting as obstructive jaundice secondary to extensive adenopathy.

Authors:  Nandini Nagaraj; Chukwuma Egwim; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

6.  Nonfunctional pancreatic neuroendocrine tumours misdiagnosed as autoimmune pancreatitis: A case report and review of literature.

Authors:  Zi-Qi Lin; Xin Li; Yan Yang; Yi Wang; Xiao-Ying Zhang; Xiao-Xin Zhang; Jia Guo
Journal:  World J Clin Cases       Date:  2022-05-26       Impact factor: 1.534

Review 7.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

Review 8.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

9.  Prognostic value of the 2017 World Health Organization Classification System for gastric neuroendocrine tumors: A single-center experience.

Authors:  Yusuf Karakaş; Şahin Laçin; Olcay Kurtulan; Ece Esin; Veli Sunar; Cenk Sökmensüer; Saadettin Kılıçkap; Şuayib Yalçin
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

Review 10.  Non-functioning pancreatic neuroendocrine tumors: Surgery or observation?

Authors:  Yehonatan Bar-Moshe; Haggi Mazeh; Simona Grozinsky-Glasberg
Journal:  World J Gastrointest Endosc       Date:  2017-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.